Sarah Cannon Research Institute
Caressa Lietman currently serves as the Associate Director of Therapeutic Development at the Sarah Cannon Research Institute, focusing on Lung Cancer and Melanoma & Skin Cancer Research Programs since April 2022. Prior to this role, Caressa held various positions at Sarah Cannon, including Senior Program Manager, Program Manager, and Program Management Associate from June 2018 to May 2022. Caressa's experience also includes a postdoctoral associate role at Vanderbilt University and a brief engagement as a postdoctoral associate at Insight Genetics Inc. Before this, Caressa worked as a Quality and Regulatory Intern at Baylor College of Medicine, where foundational academic training was completed, earning a Ph.D. in Molecular and Human Genetics from Baylor College of Medicine in 2014 and a BS in Biotechnology from the Rochester Institute of Technology in 2009.
This person is not in the org chart
This person is not in any teams
Sarah Cannon Research Institute
Sarah Cannon Research Institute (SCRI) is one of the world’s leading oncology research organizations conducting community-based clinical trials. In 2022, SCRI formed a joint venture with former US Oncology Research to enhance clinical trial access and availability across the country. Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development. It has conducted nearly 700 first-in-human clinical trials since its inception and contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA today. The combined research network brings together physicians who are actively accruing patients to clinical trials at more than 250 locations in 26 states across the US.